Sepsis Diagnostics Market Size- By Product, By Technology, By Method Type, & Forecast to 2034

Global Sepsis Diagnostics Market Size- By Product, By Technology, By Method Type, By Pathogen Type, By End-User- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Published: Jul-2025 Report ID: HLCA25197 Pages: 1 - 259 Formats*:     
Category : Healthcare
Sepsis Diagnostics Market Introduction and Overview 

According to SPER Market Research, the Global Sepsis Diagnostics Market is estimated to reach USD 1498.27 million by 2034 with a CAGR of 7.63%.

The report includes an in-depth analysis of the Global Sepsis Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis. The global Sepsis Diagnostics market was valued at USD 718.22 million in 2024 and is projected to increase at a compound annual growth rate (CAGR) of 7.63% between 2025 and 2034. Rising awareness about infectious diseases and the importance of their early detection is expected to significantly drive the growth of the sepsis diagnostics market. Sepsis diagnostics involve methods used to identify sepsis, a critical and potentially fatal condition that arises when the body’s response to an infection causes widespread inflammation, leading to organ dysfunction or failure. Accurate and timely diagnosis is essential, as sepsis can progress rapidly if left untreated. The growing demand for effective diagnostic tools and systems that enable quick identification of sepsis cases is likely to enhance the market’s expansion in the coming years.
By Product Insights
Based on Product, the sepsis diagnostics market, when analyzed by product type, is segmented into instruments, assay kits and reagents, blood culture media, and software. Among these, blood culture media play a key role due to their cost-effectiveness and widespread market availability. These media are commonly used by hospitals and diagnostic laboratories, which has positively impacted their demand. Their convenience and affordability make them a preferred option compared to other sepsis diagnostic tools, thereby driving their continued adoption and supporting overall market growth.

By Technology Insights
Based on Technology, when categorized by technology, the sepsis diagnostics market includes microbiology, molecular diagnostics, immunoassays, and flow cytometry. Among these, microbiology has experienced the fastest growth due to its affordability and the ability to accurately detect and identify infection-causing microorganisms. The strong reliance on blood culture techniques in diagnosing sepsis supports this trend. The combination of precision and low cost has made microbiology a widely accepted technology in both clinical and laboratory settings.

By Method Type Insights
In terms of diagnostic method, the market is divided into conventional and automated diagnostics. Conventional diagnostics currently represent a major share due to their role in ensuring early disease detection and timely medical intervention. These methods depend on the professional judgment of healthcare experts who interpret lab and imaging data for accurate results. Furthermore, their relatively lower cost compared to automated systems makes them a viable choice, particularly in resource-limited settings, contributing to their steady market presence.

By Pathogen Type Insights
Based on Pathogen Type, the market segmentation by pathogen type includes bacterial sepsis, fungal sepsis, and others. Bacterial sepsis remains the dominant segment owing to the rise in cases linked to post-surgical infections and the growing prevalence of healthcare-associated infections. Individuals with pre-existing health conditions are particularly vulnerable to such infections, which often progress to bacterial sepsis. This increased incidence has led to a greater need for diagnostic tools tailored to bacterial pathogens.

By End-User Insights
By end-user, the market is categorized into hospitals, clinics, diagnostic centers, and others. Hospitals have emerged as the leading users of sepsis diagnostics due to the high volume of patients and rising awareness about the severity of sepsis. With more focus on improving patient outcomes and the availability of research-driven laboratories within hospitals, the demand for effective sepsis diagnostic tools has surged. In developed regions, increasing healthcare spending and better access to diagnostics further reinforce hospital dominance in this market.

Regional Insights
The demand for sepsis diagnostics in North America has grown significantly due to the presence of advanced healthcare infrastructure and the adoption of cutting-edge diagnostic technologies. Additionally, the increasing occurrence of hospital-acquired infections largely driven by a rise in surgical procedures and continuous technological advancements is expected to further support market growth in the region over the coming years.



Market Competitive Landscape
Leading companies in the sepsis diagnostics market focus on innovation, strategic partnerships, and advanced technologies to expand globally, improve accuracy, and meet the growing demand for rapid diagnostic solutions.
Some key players are- Abbott Laboratories, BioMérieux SA, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter Inc, T2 Biosystems Inc, Nanosphere Inc, Hoffmann-La Roche Ltd, and Danaher Corporation.

Recent Developments:
In June 2023, Inflammatix received FDA clearance for its TriVerityâ„¢ system, a diagnostic test that measures multiple mRNA markers to distinguish bacterial from viral infections and assess sepsis severity. This advanced technology supports quicker, more accurate diagnosis, expected to drive demand and expansion in the sepsis diagnostics market.
In March 2023, Cytovale launched the IntelliSep® rapid sepsis test in the U.S., which uses machine learning and microfluidics to detect early sepsis signs within 8 minutes. This FDA-cleared device has improved patient management by enabling faster diagnosis and reducing unnecessary hospital stays, contributing positively to market growth.

Scope of the report:
 Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
 Forecast period 2025-2034
Segments coveredBy Product, By Technology, By Method Type, By Pathogen Type, By End-User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Abbott Laboratories, BioMérieux SA, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter Inc, T2 Biosystems Inc, Nanosphere Inc, Hoffmann-La Roche Ltd, Danaher Corporation.

Key Topics Covered in the Report
  • Global Sepsis Diagnostics Market Size (FY’2021-FY’2034)
  • Overview of Global Sepsis Diagnostics Market
  • Segmentation of Global Sepsis Diagnostics Market By Product (Blood culture media, Instruments, Assay kits & reagents, Software)
  • Segmentation of Global Sepsis Diagnostics Market By Technology (Microbiology, Molecular diagnostics, Immunoassays, Flow cytometry)
  • Segmentation of Global Sepsis Diagnostics Market By Method Type (Conventional diagnostics, Automated diagnostics)
  • Segmentation of Global Sepsis Diagnostics Market By Pathogen Type (Bacterial sepsis, Fungal sepsis, Others)
  • Segmentation of Global Sepsis Diagnostics Market By End-User (Hospitals, Diagnostic centres, Clinics, Others)
  • Statistical Snap of Global Sepsis Diagnostics Market
  • Expansion Analysis of Global Sepsis Diagnostics Market
  • Problems and Obstacles in Global Sepsis Diagnostics Market
  • Competitive Landscape in the Global Sepsis Diagnostics Market
  • Details on Current Investment in Global Sepsis Diagnostics Market
  • Competitive Analysis of Global Sepsis Diagnostics Market
  • Prominent Players in the Global Sepsis Diagnostics Market
  • SWOT Analysis of Global Sepsis Diagnostics Market
  • Global Sepsis Diagnostics Market Future Outlook and Projections (FY’2025-FY’2034)
1.Introduction
1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data
2.1.2.Primary Data
2.1.3.SPERs internal database
2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers
4.1.2.Restraints
4.1.3.Opportunities
4.1.4.Challenges

5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths
5.1.2.Weaknesses
5.1.3.Opportunities
5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape
5.2.2.Economic Landscape
5.2.3.Social Landscape
5.2.4.Technological Landscape
5.2.5.Environmental Landscape
5.2.6.Legal Landscape
5.3.PORTERs Five Forces 
5.3.1.Bargaining power of suppliers
5.3.2.Bargaining power of buyers
5.3.3.Threat of Substitute
5.3.4.Threat of new entrant
5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape
6.1.Global Sepsis Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type 
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Sepsis Diagnostics Market

7.Global Sepsis Diagnostics Market, By Product (USD Million) 2021-2034
7.1.Blood culture media
7.2.Instruments
7.3.Assay kits & reagents
7.4.Software 

8.Global Sepsis Diagnostics Market, By Technology (USD Million) 2021-2034
8.1.Microbiology
8.2.Molecular diagnostics
8.3.Immunoassays
8.4.Flow cytometry

9.Global Sepsis Diagnostics Market, By Method Type (USD Million) 2021-2034
9.1.Conventional diagnostics
9.2.Automated diagnostics

10.Global Sepsis Diagnostics Market, By Pathogen Type (USD Million) 2021-2034
10.1.Bacterial sepsis
10.2.Fungal sepsis
10.3.Others

11.Global Sepsis Diagnostics Market, By End-User (USD Million) 2021-2034
11.1.Hospitals
11.2.Diagnostic centres
11.3.Clinics
11.4.Others

12.Global Sepsis Diagnostics Market, (USD Million) 2021-2034
12.1.Global Sepsis Diagnostics Market Size and Market Share

13.Global Sepsis Diagnostics Market, By Region, (USD Million) 2021-2034
13.1.Asia-Pacific
13.1.1.Australia
13.1.2.China
13.1.3.India
13.1.4.Japan
13.1.5.South Korea
13.1.6.Rest of Asia-Pacific
13.2.Europe
13.2.1.France
13.2.2.Germany
13.2.3.Italy
13.2.4.Spain
13.2.5.United Kingdom
13.2.6.Rest of Europe
13.3.Middle East and Africa
13.3.1.Kingdom of Saudi Arabia 
13.3.2.United Arab Emirates
13.3.3.Qatar
13.3.4.South Africa
13.3.5.Egypt
13.3.6.Morocco
13.3.7.Nigeria
13.3.8.Rest of Middle-East and Africa
13.4.North America
13.4.1.Canada
13.4.2.Mexico
13.4.3.United States
13.5.Latin America
13.5.1.Argentina
13.5.2.Brazil
13.5.3.Rest of Latin America 

14.Company Profile
14.1.Abbott Laboratories
14.1.1.Company details
14.1.2.Financial outlook
14.1.3.Product summary 
14.1.4.Recent developments
14.2.BioMerieux SA
14.2.1.Company details
14.2.2.Financial outlook
14.2.3.Product summary 
14.2.4.Recent developments
14.3.Thermo Fisher Scientific Inc
14.3.1.Company details
14.3.2.Financial outlook
14.3.3.Product summary 
14.3.4.Recent developments
14.4.Becton, Dickinson, and Company
14.4.1.Company details
14.4.2.Financial outlook
14.4.3.Product summary 
14.4.4.Recent developments
14.5.Bruker Corporation
14.5.1.Company details
14.5.2.Financial outlook
14.5.3.Product summary 
14.5.4.Recent developments
14.6.Beckman Coulter, Inc
14.6.1.Company details
14.6.2.Financial outlook
14.6.3.Product summary 
14.6.4.Recent developments
14.7.Danaher Corporation
14.7.1.Company details
14.7.2.Financial outlook
14.7.3.Product summary 
14.7.4.Recent developments
14.8.Hoffmann-LA Roche Ltd
14.8.1.Company details
14.8.2.Financial outlook
14.8.3.Product summary 
14.8.4.Recent developments
14.9.Nanosphere, Inc
14.9.1.Company details
14.9.2.Financial outlook
14.9.3.Product summary 
14.9.4.Recent developments
14.10.T2 Biosystems, Inc
14.10.1.Company details
14.10.2.Financial outlook
14.10.3.Product summary 
14.10.4.Recent developments
14.11.Others

15.Conclusion

16.List of Abbreviations

17.Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
Sepsis Diagnostics Market is projected to reach USD 1498.27 by 2034, growing at a CAGR of 7.63 % during the forecast period.
Sepsis Diagnostics Market size from 2025. The Market is expected to reach USD 1498.27 by 2034, at a CAGR of 7.63% during the forecast period.
Sepsis Diagnostics Market CAGR of 7.63% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Sepsis Diagnostics Market size is USD 1498.27 from 2025 to 2034.
Sepsis Diagnostics Market covered By Product, By Technology, By Method Type, By Pathogen Type, By End-User
The North America is anticipated to have the highest Market share in the Sepsis Diagnostics Market .
" Abbott Laboratories, BioMérieux SA, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter Inc, T2 Biosystems Inc, Nanosphere Inc, Hoffmann-La Roche Ltd, Danaher Corporation."
The report includes an in-depth analysis of the Global Sepsis Diagnostics Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
  • 15 % off
     
    $ 4250
  • 20 % off
             
    $ 5650
  • 25 % off
         
    $ 7450
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Have a glance of the Report

  Download Free Sample

Looking for Customization?

 Customization Request

Have a Question?

 Reach Our Analysis Team

COVID-19 impact analysis?

 Request Analysis

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken